6XSW
Structure of the Notch3 NRR in complex with an antibody Fab Fragment
6XSW の概要
| エントリーDOI | 10.2210/pdb6xsw/pdb |
| 分子名称 | Anti-N3 Fab Heavy Chain, Anti-N3 Fab Light Chain, Neurogenic locus notch homolog protein 3, ... (7 entities in total) |
| 機能のキーワード | notch3, antibody, signaling protein, signaling protein-immune system complex, signaling protein/immune system |
| 由来する生物種 | Rattus norvegicus 詳細 |
| タンパク質・核酸の鎖数 | 12 |
| 化学式量合計 | 318978.95 |
| 構造登録者 | |
| 主引用文献 | Geles, K.G.,Gao, Y.,Giannakou, A.,Sridharan, L.,Yamin, T.T.,Zhang, J.,Karim, R.,Bard, J.,Piche-Nicholas, N.,Charati, M.,Maderna, A.,Lucas, J.,Golas, J.,Guffroy, M.,Pirie-Shepherd, S.,Roy, M.,Qian, J.,Franks, T.,Zhong, W.,O'Donnell, C.J.,Tchistiakova, L.,Gerber, H.P.,Sapra, P. NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells. Cell Rep Med, 2:100279-100279, 2021 Cited by PubMed Abstract: Aberrant NOTCH3 signaling and overexpression is oncogenic, associated with cancer stem cells and drug resistance, yet therapeutic targeting remains elusive. Here, we develop NOTCH3-targeted antibody drug conjugates (NOTCH3-ADCs) by bioconjugation of an auristatin microtubule inhibitor through a protease cleavable linker to two antibodies with differential abilities to inhibit signaling. The signaling inhibitory antibody rapidly induces ligand-independent receptor clustering and internalization through both caveolin and clathrin-mediated pathways. The non-inhibitory antibody also efficiently endocytoses via clathrin without inducing receptor clustering but with slower lysosomal co-localization kinetics. In addition, DLL4 ligand binding to the NOTCH3 receptor mediates transendocytosis of NOTCH3-ADCs into ligand-expressing cells. NOTCH3-ADCs internalize into receptor and ligand cells independent of signaling and induce cell death in both cell types representing an atypical mechanism of ADC cytotoxicity. Treatment of xenografts with NOTCH3-ADCs leads to sustained tumor regressions, outperforms standard-of-care chemotherapy, and allows targeting of tumors that overexpress NOTCH3 independent of signaling inhibition. PubMed: 34095881DOI: 10.1016/j.xcrm.2021.100279 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.98 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






